32519-69-0

Basic information

• Product Name: N-(5-acetyl-4-methylthiazol-2-yl)benzamide
• Synonyms: N-(5-acetyl-4-methylthiazol-2-yl)benzamide
• CAS NO: 32519-69-0
• Molecular Weight: 260.316
• Mol File: 32519-69-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(5-acetyl-4-methylthiazol-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-acetyl-4-methylthiazol-2-yl)benzamide(32519-69-0)
• EPA Substance Registry System: N-(5-acetyl-4-methylthiazol-2-yl)benzamide(32519-69-0)

Safety Data

• Hazardous Substances Data: 32519-69-0(Hazardous Substances Data)

Upstream product

• 614-23-3 N-benzoylthiourea 
• 1694-29-7 3-chloropentane-2,4-dione 
• 98-88-4 benzoyl chloride 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 32558-16-0 N-[5-(2-bromoacetyl)-4-methylthiazol-2-yl]benzamide 
• 1402464-39-4 C₁₇H₁₆N₂O₅S 
• 1395082-14-0 N-(4-methyl-5-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetyl)thiaz-ol-2-yl)benzamide 
• 1395082-15-1 N-(5-(2-(4-(methoxymethyl)-1H-1,2,3-triazol-1-yl)acetyl)-4-methylthiazol-2-yl)benzamide 
• 1395082-16-2 N-(4-methyl-5-(2-(4-(morpholinomethyl)-1H-1,2,3-triazol-1-yl)acetyl)thiazol-2-yl)benzamide 
• 1391715-61-9 N-(5-(2-azidoacetyl)-4-methylthiazol-2-yl)benzamide 
• 39884-28-1 1-(2-benzoylamino-4-methyl-thiazol-5-yl)-ethanol 
• 36975-15-2 N-(5-acetyl-4-methylthiazol-2-yl)-3-nitrobenzamide 

Relevant articles and documents

Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase

A hybrid pharmacophore approach is used to design and synthesize novel chalcone-thiazole hybrid molecules. Herein, thiazole has been hybridized with chalcone to obtain a new class of 5-LOX inhibitors. In vitro biological evaluation showed that most of the compounds were better 5-LOX inhibitors than the positive control, Zileuton (IC50 = 1.05 ± 0.03 μM). The best compounds in the series, namely, 4k, 4n, and 4v (4k: IC50 = 0.07 ± 0.02 μM, 4n: IC50 = 0.08 ± 0.05 μM, 4v: 0.12 ± 0.04 μM) are found to be 10 times more active than previously reported 2-amino thiazole (2m: IC50 = 0.9 ± 0.1 μM) by us. Further, 4k has redox (noncompetitive) while 4n and 4v act through a competitive inhibition mechanism. SAR indicated that the presence of methoxy/methyl either in the vicinity of chalcone or both thiazole and chalcone contributed to the synergistic inhibitory effect.

Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein ΔF508-CFTR

A developing therapy of cystic fibrosis caused by the ΔF508 mutation in CFTR employs correction of defective CFTR chloride channel gating by a 'potentiator' and of defective CFTR protein folding by a 'corrector'. Based on SAR data for phenylglycine-type potentiators and bithiazole correctors, we designed a hybrid molecule incorporating an enzymatic hydrolysable linker to deliver the potentiator (PG01) fragment 2 and the corrector (Corr-4a) fragment 13. The hybrid molecule 14 contained PG01-OH and Corr-4a-linker-CO2H moieties, linked with an ethylene glycol spacer through an ester bond. The potentiator 2 and corrector 13 fragments (after cleavage) had low micromolar potency for restoration of ΔF508-CFTR channel gating and cellular processing, respectively. Cleavage of hybrid molecule 14 by intestinal enzymes under physiological conditions produced the active potentiator 2 and corrector fragments 13, providing proof-of-concept for small-molecule potentiator-corrector hybrids as a single drug therapy for CF caused by the ΔF508 mutation.